Sofinnova Investments Inc. increased its stake in shares of Dermira Inc (NASDAQ:DERM) by 9.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 542,224 shares of the biopharmaceutical company’s stock after buying an additional 46,931 shares during the quarter. Sofinnova Investments Inc. owned about 1.29% of Dermira worth $3,899,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of DERM. SG Americas Securities LLC acquired a new stake in Dermira during the third quarter worth approximately $946,000. Teachers Retirement System of The State of Kentucky lifted its stake in Dermira by 25.2% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 42,915 shares of the biopharmaceutical company’s stock worth $468,000 after purchasing an additional 8,640 shares during the last quarter. Panagora Asset Management Inc. lifted its stake in Dermira by 1,929.5% during the third quarter. Panagora Asset Management Inc. now owns 122,988 shares of the biopharmaceutical company’s stock worth $1,341,000 after purchasing an additional 116,928 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Dermira by 48.0% during the third quarter. Dimensional Fund Advisors LP now owns 920,605 shares of the biopharmaceutical company’s stock worth $10,034,000 after purchasing an additional 298,677 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Dermira during the third quarter worth $2,085,000. 87.40% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have weighed in on DERM. Needham & Company LLC restated a “buy” rating and set a $22.00 target price (up from $16.00) on shares of Dermira in a research note on Monday. HC Wainwright upped their target price on Dermira from $13.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday. Zacks Investment Research upgraded Dermira from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a research note on Wednesday, February 20th. Mizuho upped their target price on Dermira from $10.00 to $17.00 and gave the stock a “positive” rating in a research note on Thursday, March 21st. They noted that the move was a valuation call. Finally, BidaskClub cut Dermira from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 15th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $17.36.

Shares of DERM traded up $0.09 during trading hours on Thursday, reaching $13.11. The stock had a trading volume of 4,292 shares, compared to its average volume of 4,562,810. Dermira Inc has a 12 month low of $6.00 and a 12 month high of $14.91. The stock has a market capitalization of $698.00 million, a price-to-earnings ratio of -2.50 and a beta of 1.34. The company has a debt-to-equity ratio of 5.21, a quick ratio of 8.48 and a current ratio of 8.70.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.70) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.75) by $0.05. Dermira had a negative return on equity of 309.23% and a negative net margin of 523.25%. As a group, equities analysts forecast that Dermira Inc will post -5.43 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.watchlistnews.com/sofinnova-investments-inc-has-3-90-million-position-in-dermira-inc-derm/2923683.html.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Featured Article: What is a Swap?

Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira Inc (NASDAQ:DERM).

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.